{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:20:12Z","timestamp":1790364012534,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Vaccination against SARS-CoV-2 using mRNA-based vaccines has been highly recommended for fragile subjects, including myelofibrosis patients (MF). Available data on the immune responsiveness of MF patients to mRNA SARS-CoV-2 vaccination, and the impact of the therapy with the JAK inhibitor ruxolitinib, are still fragmented. Here, we profile the spike-specific IgG and memory B-cell response in MF patients, treated or not with ruxolitinib, after the second and the third dose of SARS-CoV-2 BNT162b2 (BioNTech) and mRNA-1273 (Moderna) vaccines. Plasma and peripheral blood mononuclear cells samples were collected before vaccination, post the second and the third doses and tested for spike-specific antibodies, ACE2\/RBD antibody inhibition binding activity and spike-specific B cells. The third vaccine dose significantly increased the spike-specific IgG titers in both ruxolitinib-treated and untreated patients, and strongly enhanced the percentage of subjects with antibodies capable of <jats:italic>in vitro<\/jats:italic> blocking ACE2\/RBD interaction, from 50% up to 80%. While a very low frequency of spike-specific B cells was measured in blood 7 days after the second vaccination dose, a strong and significant increase was elicited by the third dose administration, generating a B cell response similar to the one detected in healthy controls. Despite the overall positive impact of the third dose in MF patients, two patients that were under active concomitant immunosuppressive treatment at the time of vaccination, and a patient that received lymphodepleting therapies in the past, remained low responders. The third mRNA vaccine dose strongly increases the SARS-CoV-2 specific humoral and B cell responses in MF patients, promoting a reactivation of the immune response similar to the one observed in healthy controls.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1017863","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T05:07:51Z","timestamp":1664428071000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Fabio","family":"Fiorino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Ciabattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sicuranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabiria","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Simoncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Polvere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Barat\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Sammartano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Montagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donata","family":"Medaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/iub.2536","article-title":"One-year mortality and consequences of COVID-19 in cancer patients: A cohort study","volume":"73","author":"Chai","year":"2021","journal-title":"IUBMB Life"},{"key":"B4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaoncol.2021.5148","article-title":"Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer","volume":"8","author":"Chavez-MacGregor","year":"2022","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100931","article-title":"COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research","volume":"54","author":"Wang","year":"2022","journal-title":"Blood Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24592","article-title":"Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0284-z","article-title":"Immunological consequences of JAK inhibition: Friend or foe","volume":"10","author":"McLornan","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00466","article-title":"Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease","volume":"7","author":"Capochiani","year":"2020","journal-title":"Anal Data Collection From RESPIRE Protocol Front Med (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0891-0","article-title":"The janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation","volume":"34","author":"La Ros\u00e9e","year":"2020","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01107-y","article-title":"High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101480","article-title":"The slower antibody response in myelofibrosis patients after two doses of mRNA SARS-CoV-2 vaccine calls for a third dose","volume":"9","author":"Fiorino","year":"2021","journal-title":"Biomedicines"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00579-0","article-title":"Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms","volume":"11","author":"Cattaneo","year":"2021","journal-title":"A single-center experience Blood Cancer J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006599","article-title":"A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses","volume":"6","author":"Pettini","year":"2022","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26305","article-title":"Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib","volume":"96","author":"Guglielmelli","year":"2021","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04613-w","article-title":"Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis","volume":"101","author":"Caocci","year":"2021","journal-title":"Ann Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-021-01130-1","article-title":"Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.826537","article-title":"Impaired antibody response following the second dose of the BNT162b2 vaccine in patients with myeloproliferative neoplasms receiving ruxolitinib","volume":"9","author":"Ikeda","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-022-00373-7","article-title":"Robust induction of b cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine","volume":"8","author":"Liu","year":"2022","journal-title":"Cell Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00078","article-title":"Origin and function of circulating plasmablasts during acute viral infections","volume":"3","author":"Fink","year":"2012","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-022-01129-w","article-title":"Characterization of nanoparticles-based vaccines for COVID-19","volume":"17","author":"Guerrini","year":"2022","journal-title":"Nat Nanotechnol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.740708","article-title":"Evidence of SARS-CoV-2-Specific memory b cells six months after vaccination with the BNT162b2 mRNA vaccine","volume":"12","author":"Ciabattini","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Regional Health - Europe"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-021-00947-3","article-title":"Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the united kingdom","volume":"6","author":"Wei","year":"2021","journal-title":"Nat Microbiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280163","article-title":"Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: A systematic review and meta-analysis","volume":"107","author":"Gagelmann","year":"2022","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2022.2038539","article-title":"Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 pfizer-BioNTech mRNA vaccination: a systematic review","volume":"59","author":"Notarte","year":"2022","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27688","article-title":"Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review","volume":"94","author":"Notarte","year":"2022","journal-title":"J Med Virol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00617-5","article-title":"Vaccination in patients with kidney failure: Lessons from COVID-19","author":"Babel","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-020-00821-0","article-title":"Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population","volume":"42","author":"Ciabattini","year":"2020","journal-title":"Semin Immunopathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","article-title":"Vaccination in the elderly: The challenge of immune changes with aging","volume":"40","author":"Ciabattini","year":"2018","journal-title":"Semin Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"New Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12339","article-title":"Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses","volume":"326","author":"Benotmane","year":"2021","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.19885","article-title":"Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged \u226560 years","volume":"326","author":"Eliakim-Raz","year":"2021","journal-title":"JAMA"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27644","article-title":"Third dose of SARS-CoV-2 vaccine: A systematic review of 30 published studies","volume":"94","author":"Petrelli","year":"2022","journal-title":"J Med Virol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.855723","article-title":"mRNA-COVID19 vaccination can be considered safe and tolerable for frail patients","volume":"12","author":"Lupo-Stanghellini","year":"2022","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1038\/s41467-021-23173-1","article-title":"Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice","volume":"12","author":"Spencer","year":"2021","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":":104073","DOI":"10.1016\/j.ebiom.2022.104073","article-title":"Heterologous ChAdOx1\/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial","volume":"80","author":"B\u00e1nki","year":"2022","journal-title":"eBioMedicine"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10010072","article-title":"Immunogenicity of a heterologous prime-boost COVID-19 vaccination with mRNA and inactivated virus vaccines compared with homologous vaccination strategy against SARS-CoV-2 variants","volume":"10","author":"Zhang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106819","article-title":"Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity","volume":"116","author":"Auteri","year":"2022","journal-title":"Leuk Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.852158","article-title":"Seroconversion to mRNA SARS-CoV-2 vaccines in hematologic patients","volume":"13","author":"Fattizzo","year":"2022","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"ciac404","DOI":"10.1093\/cid\/ciac404","article-title":"Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study","author":"Corradini","year":"2022","journal-title":"Clin Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1017863\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T05:07:53Z","timestamp":1664428073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1017863\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2022.1017863"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1017863","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"article-number":"1017863"}}